Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alexandra Solomos"'
Autor:
Ahmed M, Musa, Jane, Mbui, Rezika, Mohammed, Joseph, Olobo, Koert, Ritmeijer, Gabriel, Alcoba, Gina, Muthoni Ouattara, Thaddaeus, Egondi, Prossy, Nakanwagi, Truphosa, Omollo, Monique, Wasunna, Luka, Verrest, Thomas P C, Dorlo, Brima, Musa Younis, Ali, Nour, Elmukashfi, Taha Ahmed Elmukashfi, Ahmed, Ismail Omer Haroun, Eltahir A G, Khalil, Simon, Njenga, Helina, Fikre, Tigist, Mekonnen, Dagnew, Mersha, Kasaye, Sisay, Patrick, Sagaki, Jorge, Alvar, Alexandra, Solomos, Fabiana, Alves
Publikováno v:
Clinical Infectious Diseases. 76:e1177-e1185
Background This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa. Methods An open-label, phase 3,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfe571622e1e72782a5232658c426563
https://doi.org/10.1093/cid/ciac643
https://doi.org/10.1093/cid/ciac643
Autor:
Alexandra Solomos, Ahmed Eleojo Musa, Monique Wasunna, Semra Palić, Jos H. Beijnen, Joseph Olobo, Thomas P. C. Dorlo, Anke E. Kip, Fabiana Alves, Jane Mbui
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background Conventional miltefosine dosing (2.5 mg/kg/day) for treatment of visceral leishmaniasis (VL) is less effective in children than in adults. A higher allometric dose (median 3.2 mg/kg/day) was therefore investigated in paediatric VL patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca7df67f2f2dc96d8e3520ab38b9fc84
http://europepmc.org/articles/PMC7566410
http://europepmc.org/articles/PMC7566410
Autor:
Graeme Bilbe, Séverine Blesson, Gina Muthoni Ouattara, Byron Arana, Joelle Rode, Vishal Goyal, Susan Wells, Alexandra Solomos, Nathalie Strub-Wourgaft, Eduard E. Zijlstra, Séverine Monnerat, Fabiana Alves, Bernard Pécoul, Monique Wasunna, Suman Rijal, Jorge Alvar, Charles E. Mowbray
Publikováno v:
Clinical Microbiology Reviews. 31
SUMMARY Research in visceral leishmaniasis in the last decade has been focused on how better to use the existing medicines as monotherapy or in combination. Systematic research by geographical regions has shown that a universal treatment is far from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a9259a569cf8854c1efa1ee3aa70840
https://doi.org/10.1128/cmr.00048-18
https://doi.org/10.1128/cmr.00048-18
Autor:
Jorge Alvar, Thaddaeus Egondi, Alexandra Solomos, Joseph Olobo, Anke E. Kip, Lilian Were, Truphosa Omollo, Patrick Sagaki, G. Kirigi, Fabiana Alves, Thomas P. C. Dorlo, Robert Kimutai, Jane Mbui, Monique Wasunna, Raymond Omollo
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Convenient, safe, and effective treatments for visceral leishmaniasis in Eastern African children are lacking. Miltefosine, the only oral treatment, failed to achieve adequate efficacy, particularly in children, in whom linear dosing (2.5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::084a183a8887aa07ddc3e2e7ab4a4753
https://pubmed.ncbi.nlm.nih.gov/30188978
https://pubmed.ncbi.nlm.nih.gov/30188978